Piper Sandler initiated coverage of RxSight (RXST) with a Neutral rating and $18 price target The firm likes the company’s novel light adjustable lens technology and that it plays in the “massive” innovative intraocular lens marketplace. However, Piper is taking a “wait-and-see approach” given its concerns about current visibility into the business, recent competitive developments, and a potentially weakening macro environment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- Cautious Hold on RxSight Amid Market Challenges and Competitive Pressures
- Apple, Starbucks upgraded: Wall Street’s top analyst calls
- RxSight downgraded to Neutral from Buy at UBS
- RxSight’s Market Challenges and Revised Growth Projections Lead to Hold Rating
- RxSight’s Strategic Growth and Resilience Justify Buy Recommendation